The worldwide pandemic of the novel coronavirus disease 2019 (COVID-19) has raised many challenges and uncertainties regarding disease management and prognosis in immunocompromised patient populations. The concurrence of human immunodeficiency… Click to show full abstract
The worldwide pandemic of the novel coronavirus disease 2019 (COVID-19) has raised many challenges and uncertainties regarding disease management and prognosis in immunocompromised patient populations. The concurrence of human immunodeficiency virus (HIV) infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, presents an intriguing problem and only a handful of these cases exist in the literature, despite 37.9 million people living with HIV throughout the world. Previous reports suggest the possibility of a protective factor from standard antiretroviral treatment for HIV patients that could have significant clinical benefits for these patients when co-infected with SARS-CoV-2. HIV patients also generally present with atypical clinical presentation and have a less severe form of COVID-19 than the general population. Here, we present the first case of an HIV positive patient who was diagnosed with COVID-19 in the United States. This article is protected by copyright. All rights reserved.
               
Click one of the above tabs to view related content.